Association between red cell distribution width-to-platelet ratio and short-term and long-term mortality risk in patients with acute ischemic stroke.
Acute ischemic stroke
Mortality risk
Platelet
Ratio
Red cell distribution width
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
15 May 2023
15 May 2023
Historique:
received:
16
03
2023
accepted:
19
04
2023
medline:
17
5
2023
pubmed:
16
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
The objective of this study was to evaluate the association between red cell distribution width/platelet ratio (RPR) and 30-day and 1-year mortality in acute ischemic stroke (AIS). Data for the retrospective cohort study were collected from the Medical Information Mart for Intensive Care (MIMIC) III database. RPR was divided into two groups: RPR ≤ 0.11 and RPR > 0.11. The study outcomes were 30-day mortality and 1-year mortality from AIS. Cox proportional hazard models were utilized to assess the association between RPR and mortality. Subgroup analyses were applied based on age, tissue-type plasminogen activator (IV-tPA), endovascular treatment, and myocardial infarction. A total of 1,358 patients were included in the study. Short- and long-term mortality occurred in 375 (27.61%) and 560 (41.24%) AIS patients, respectively. A high RPR was significantly associated with increased 30-day [hazard ratio (HR): 1.45, 95% confidence interval (CI): 1.10 to 1.92, P = 0.009] and 1-year mortality (HR: 1.54, 95%CI: 1.23 to 1.93, P < 0.001) in AIS patients. Meanwhile, RPR was found to be significantly related to 30-day mortality in AIS patients aged < 65 years (HR: 2.19, 95% CI: 1.17 to 4.10, P = 0.014), without IV-tPA use (HR: 1.42, 95% CI: 1.05 to 1.90, P = 0.021), without using endovascular treatment (HR: 1.45, 95% CI: 1.08 to 1.94, P = 0.012), and without myocardial infarction (HR: 1.54, 95% CI: 1.13 to 2.10, P = 0.006). Additionally, RPR was associated with 1-year mortality in AIS patients aged < 65 years (HR: 2.54, 95% CI: 1.56 to 4.14, P < 0.001), aged ≥ 65 years (HR: 1.38, 95% CI: 1.06 to 1.19, P = 0.015), with (HR: 1.46, 95% CI: 1.15 to 1.85, P = 0.002) and without using IV-tPA (HR: 2.30, 95% CI: 1.03 to 5.11, P = 0.041), without using endovascular treatment (HR: 1.56, 95% CI: 1.23 to 1.96, P < 0.001), and without myocardial infarction (HR: 1.68, 95% CI: 1.31 to 2.15, P < 0.001). Elevated RPR is associated with a high risk of short-term and long-term mortality in AIS.
Sections du résumé
BACKGROUND
BACKGROUND
The objective of this study was to evaluate the association between red cell distribution width/platelet ratio (RPR) and 30-day and 1-year mortality in acute ischemic stroke (AIS).
METHODS
METHODS
Data for the retrospective cohort study were collected from the Medical Information Mart for Intensive Care (MIMIC) III database. RPR was divided into two groups: RPR ≤ 0.11 and RPR > 0.11. The study outcomes were 30-day mortality and 1-year mortality from AIS. Cox proportional hazard models were utilized to assess the association between RPR and mortality. Subgroup analyses were applied based on age, tissue-type plasminogen activator (IV-tPA), endovascular treatment, and myocardial infarction.
RESULTS
RESULTS
A total of 1,358 patients were included in the study. Short- and long-term mortality occurred in 375 (27.61%) and 560 (41.24%) AIS patients, respectively. A high RPR was significantly associated with increased 30-day [hazard ratio (HR): 1.45, 95% confidence interval (CI): 1.10 to 1.92, P = 0.009] and 1-year mortality (HR: 1.54, 95%CI: 1.23 to 1.93, P < 0.001) in AIS patients. Meanwhile, RPR was found to be significantly related to 30-day mortality in AIS patients aged < 65 years (HR: 2.19, 95% CI: 1.17 to 4.10, P = 0.014), without IV-tPA use (HR: 1.42, 95% CI: 1.05 to 1.90, P = 0.021), without using endovascular treatment (HR: 1.45, 95% CI: 1.08 to 1.94, P = 0.012), and without myocardial infarction (HR: 1.54, 95% CI: 1.13 to 2.10, P = 0.006). Additionally, RPR was associated with 1-year mortality in AIS patients aged < 65 years (HR: 2.54, 95% CI: 1.56 to 4.14, P < 0.001), aged ≥ 65 years (HR: 1.38, 95% CI: 1.06 to 1.19, P = 0.015), with (HR: 1.46, 95% CI: 1.15 to 1.85, P = 0.002) and without using IV-tPA (HR: 2.30, 95% CI: 1.03 to 5.11, P = 0.041), without using endovascular treatment (HR: 1.56, 95% CI: 1.23 to 1.96, P < 0.001), and without myocardial infarction (HR: 1.68, 95% CI: 1.31 to 2.15, P < 0.001).
CONCLUSION
CONCLUSIONS
Elevated RPR is associated with a high risk of short-term and long-term mortality in AIS.
Identifiants
pubmed: 37189031
doi: 10.1186/s12883-023-03219-1
pii: 10.1186/s12883-023-03219-1
pmc: PMC10184357
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191Informations de copyright
© 2023. The Author(s).
Références
Front Genet. 2022 Mar 14;13:810974
pubmed: 35360855
J Stroke Cerebrovasc Dis. 2022 Feb;31(2):106243
pubmed: 34896818
Ann Transl Med. 2020 Feb;8(4):81
pubmed: 32175374
Int J Gen Med. 2021 Nov 01;14:7545-7555
pubmed: 34754227
Am J Emerg Med. 2010 Mar;28(3):359-63
pubmed: 20223397
Neuropsychiatr Dis Treat. 2015 Mar 18;11:733-9
pubmed: 25834448
Semin Thromb Hemost. 2017 Feb;43(1):30-35
pubmed: 27813042
Thromb Haemost. 2007 Jun;97(6):974-8
pubmed: 17549300
PLoS One. 2010 Jul 19;5(7):e11658
pubmed: 20657835
Pol Arch Intern Med. 2019 Feb 28;129(2):117-122
pubmed: 30758314
Yonsei Med J. 2018 Mar;59(2):294-302
pubmed: 29436199
Front Neurol. 2019 Apr 12;10:370
pubmed: 31031698
J Am Heart Assoc. 2019 Aug 6;8(15):e012450
pubmed: 31327296
Aging (Albany NY). 2020 May 23;12(10):9855-9867
pubmed: 32445553
World Neurosurg. 2021 Sep;153:e282-e289
pubmed: 34217857
Int J Mol Sci. 2016 Jan 05;17(1):
pubmed: 26742037
BMJ Open. 2019 Jan 25;9(1):e022896
pubmed: 30782690
Am J Med. 2021 Dec;134(12):1457-1464
pubmed: 34454905
Rev Port Cardiol. 2015 Oct;34(10):597-606
pubmed: 26387826
Stroke Vasc Neurol. 2017 Jun 23;2(3):172-175
pubmed: 28989807
World J Gastroenterol. 2014 Oct 21;20(39):14450-4
pubmed: 25339831
Brain Sci. 2021 Aug 31;11(9):
pubmed: 34573185
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Trends Neurosci. 2018 Dec;41(12):877-879
pubmed: 30327142
Thromb Haemost. 2016 Jan;115(1):126-34
pubmed: 26290352
Mediators Inflamm. 2022 Sep 27;2022:4915887
pubmed: 36204660
Mymensingh Med J. 2018 Jul;27(3):550-560
pubmed: 30141445
Brain Sci. 2020 Oct 23;10(11):
pubmed: 33114150
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Neurointervention. 2021 Mar;16(1):34-38
pubmed: 33202515
J Nanobiotechnology. 2021 Aug 28;19(1):257
pubmed: 34454522
Medicine (Baltimore). 2020 Apr;99(16):e19691
pubmed: 32311945
Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):50-4
pubmed: 23103090
Atherosclerosis. 2000 Jan;148(1):75-85
pubmed: 10580173
Front Neurol. 2021 Nov 15;12:751510
pubmed: 34867736